-
-
-
-
-
-
-
FDA accepts Unicycive's OLC drug resubmission, sets March 2027 review date
-
-
-
-
-
-
-
Unicycive Therapeutics (UNCY) PT Lowered to $37 at Guggenheim
-
-
-
-
-
-
-
UPDATE - Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission
-
-
-
-
-
-
-
Unicycive Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Unicycive Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Unicycive Therapeutics, Inc (UNCY) Announces the Publication of Preclinical Data on Synergies Between Oxylanthanum Carbonate and Tenapanor
-
-
-
-
-
-
-
Unicycive Therapeutics to Participate in Two Upcoming Investor Conferences Including a Fireside Chat at the Piper Sandler 36th Annual Healthcare Conference
-
15,963 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


